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Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy
for noninvasive identification of mutations across multiple genetic loci and
for disease monitoring in melanoma. In this study, we compared the mutation profiles of tumor biopsies and plasma ctDNA from metastatic
melanoma patients using custom sequencing panels targeting 30 melanoma-associated genes. Somatic mutations were identified in 20 of 24
melanoma biopsies, and 16 of 20 (70%) matched-patient plasmas had
detectable ctDNA. In a subgroup of seven patients for whom matching
tumor tissue and plasma were sequenced, 80% of the mutations found in
tumor tissue were also detected in ctDNA. However, TERT promoter
mutations were only detected by ddPCR, and promoter mutations were
consistently found at lower concentrations than other driver mutations in
longitudinal samples. In vitro experiments revealed that mutations in promoter regions of TERT and DPH3 are underrepresented in ctDNA. While
the results underscore the utility of using ctDNA as an alternative to tissue
biopsy for genetic profiling and surveillance of the disease, our study highlights the underrepresentation of promoter mutations in ctDNA and its
potential impact on quantitative liquid biopsy applications.

1. Introduction
The use of targeted therapeutic agents and immune
checkpoint inhibitors has improved the survival of
metastatic melanoma patients in recent years (Luke

et al., 2017). Current treatment strategies employ various systemic agents, often used in succession, that are
dependent on the genetic landscape of the tumor
(Ascierto et al., 2013; Chen et al., 2016; Larkin et al.,
2014; Luke et al., 2017; Ribas et al., 2015; Santiago-

Abbreviations
cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; ddPCR, digital droplet PCR; FDG-PET/CT, 18F-labeled fluorodeoxyglucose positron
emission tomography/computed tomography; FFPE, formalin-fixed paraffin embedded tissue; MTB, metabolic tumor burden; NGS, nextgeneration sequencing.
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Walker et al., 2016). Treating physicians are confronted with new challenges, such as stratifying
patients for appropriate treatments and monitoring
long-term responders for progression. Consequently,
reliable methods for monitoring disease progression
and treatment response or resistance are necessary.
Circulating tumor DNA (ctDNA), which is shed
into the blood as a result of tumor cell apoptosis and
necrosis, has been shown to have potential clinical utility for molecular classification (Haselmann et al.,
2018), prognostication (Ascierto et al., 2013; Gray
et al., 2015; Knol et al., 2016; Sanmamed et al., 2015),
and monitoring patient response to therapy (Girotti
et al., 2016; Gray et al., 2015; Lee et al., 2017;
Schreuer et al., 2016; Wong et al., 2017) in melanoma.
Plasma ctDNA has also been shown to capture clonal
evolution, via identification of mutations that mediate
resistance to BRAF inhibitors (Girotti et al., 2016;
Gray et al., 2015). Moreover, the analysis of plasma
and multiple metastatic deposits in two melanoma
patients indicated that ctDNA can reflect the genetic
heterogeneity of various subclones across multiple
tumors (Wong et al., 2017). Thus, ctDNA appears to
be a useful biomarker for patient surveillance during
treatment, acting as a potential surrogate to tissue
biopsy and providing a comprehensive snapshot of the
molecular diversity of metastases. Nevertheless, the
detection rate of ctDNA in melanoma patients and
concordance of mutations between plasma and tissue
still requires further study, especially beyond detection
of BRAF mutations (Calapre et al., 2017).
Based on their somatic mutation profiles, melanomas
can be divided into four genomic subtypes: BRAF,
RAS (N/H/K), NF1, and triple wild-type (WT)
(TCGA, 2015). Recurring hotspot mutations in the
V600 codon of BRAF or Q61 codon of NRAS are the
most prevalent and occur in approximately 35–50%
and 10–25% of melanomas, respectively (Pollock et al.,
2002; TCGA, 2015; Tsao et al., 2012). Most ctDNA
studies thus far have only analyzed BRAF mutant cases
(Ascierto et al., 2013; Girotti et al., 2016; Gray et al.,
2015; Knol et al., 2016; Schreuer et al., 2016). These
studies have remarked on the high fidelity of BRAF
mutant ctDNA to reflect disease burden and tumor status of patients prior to and during treatment (Ascierto
et al., 2013; Girotti et al., 2016; Gray et al., 2015; Knol
et al., 2016; Schreuer et al., 2016). However, it is
imperative to ascertain the detection rate and kinetics
of other common melanoma-associated mutations to
determine whether they can be effectively used for
patient surveillance, particularly in BRAF WT cases.
In this study, we identified tumor mutations using a
custom next-generation sequencing (NGS) panel
172
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targeting melanoma-specific genes in a cohort of metastatic melanoma patients and determined the detection
rate of ctDNA by targeting mutations identified in
each patient’s tumor. We performed sequencing of a
set of paired melanoma tissue biopsies and circulating
free DNA (cfDNA) to determine the level of concordance of mutations across these two compartments.
Furthermore, we evaluated the suitability of various
mutated loci for monitoring ctDNA in patients undergoing systemic therapies. Finally, we performed
in vitro experiments to evaluate whether mutations in
promoter regions are underrepresented in cfDNA.

2. Materials and methods
2.1. Patients
Metastatic melanoma patients were enrolled in the study
between 2013 and 2016 at Sir Charles Gairdner Hospital
(SCGH) and Fiona Stanley Hospital (FSH) in Perth,
Western Australia. Written informed consent was
obtained from all patients under approved Human
Research Ethics Committee protocols from Edith Cowan
University (No. 11543) and Sir Charles Gairdner Hospital (No. 2007-123). The study methodologies conformed
to the standards set by the Declaration of Helsinki.
2.2. Tissue analysis
Tissue biopsies were retrospectively tested for mutation
profile. The tissue biopsies were included if obtained prior
to therapy initiation, with no systemic treatment during
that period. Hematoxylin and eosin (H&E)-stained sections were assessed by a pathologist and the percentage
of tumor cells estimated. Microdissection was performed
when the neoplastic cell content was below 50%. DNA
was isolated using QIAamp Tissue FFPE Kits (Qiagen,
Hilden, Germany) as per the manufacturer’s instructions.
FFPE gDNA was stored at 4 °C until processed for targeted NGS (Supporting Information).
2.3. Plasma sample preparation and cfDNA
extractions
Blood samples were collected prior to initiation of treatment into EDTA vacutainer or Cell-Free DNA BCT
(Streck, La Vista, NE, USA) tubes and stored at 4 °C.
Plasma was separated within 24 h by centrifugation at
300 g for 20 min, followed by a second centrifugation at
4700 g for 10 min and then stored at 80 °C until
extraction. cfDNA was isolated from 1 to 5 mL of
plasma using QIAamp Circulating Nucleic Acid Kits
(Qiagen, Hilden, Germany) as per the manufacturer’s
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instructions. cfDNA was eluted in 40 ll AVE buffer
(Qiagen, Hilden, Germany) and stored at 80 °C until
ctDNA quantification by droplet digital PCR (ddPCR)
(Supporting Information) or processed for sequencing
using a QIASeq Targeted DNA Custom Panel (CDHS12967Z-1243) (Supporting Information).
2.4. Metabolic tumor burden analysis
18

F-labeled fluorodeoxyglucose positron emission
tomography/computed tomography (FDG-PET/CT)
scans were performed on combined PET/CT scanners
at approved nuclear radiology centers in Perth, Western Australia. After a minimum fasting period of 6 h,
patients were injected with 5 MBq pr. kg 10% of
18
FDG (minimum 200 MBq and maximum 600 MBq).
PET was performed on patients with serum glucose
levels below 11 nmolL1 at an acquisition time of
3 min per bed position. To determine anatomical location and for attenuation correction purposes, a wholebody low-dose computed tomography scan was
performed. All images were reviewed retrospectively
and independently by an experienced nuclear medicine
physician, blinded to the ctDNA analysis. Analysis
was conducted on a Siemens Syngo via workstation
(Siemens Healthcare GMbH, Erlangen, Germany)
reporting the global total lesion glycolysis (TLG),
which combines volumetric and metabolic information
(Chen et al., 2012; Kim et al., 2013) and can provide a
better evaluation of Metabolic tumor burden (MTB).
2.5. Targeted amplicon sequencing and
bioinformatics of tumor tissue
Tissue biopsy mutation profiles were identified by targeted NGS using a customized panel of 30 melanomaassociated genes (Illumina, San Diego, CA, USA) with
950 amplicons and an Illumina MiSeq instrument.
Forward and reverse strand NGS libraries were prepared using the customized melanoma panel according
to the manufacturer’s instructions. In brief, forward
and reverse oligonucleotide pools were hybridized to
DNA samples overnight. Hybridized samples were
then ligated, extended, and amplified with unique
index sequences (barcodes) and sequencing adaptors.
Amplified libraries were purified using Agencourt
AMPure XP magnetic beads (Beckman Coulter, Brea,
CA, USA), first at a ratio of 1 (library):1 (beads), as
per the manufacturer’s protocol, followed by a second
round of purification at a library to bead ratio of
1.25 : 1. Library DNA concentrations were quantified
using a Qubit 3.0 fluorometer. Libraries were normalized to 4 nmolL1 in EBT buffer, pooled, and

sequenced on a MiSeq instrument (Illumina). Sequence
alignment and variant calling were performed by
ILLUMINA MISEQ REPORTER software (version 2.4,
Illumina). Genomic variants were annotated using the
ILLUMINA VARIANT STUDIO 2.2 software (Illumina). Variants with allele frequency (VAF) >3% and that passed
the software quality parameters were considered true
mutations. Polymorphisms and synonymous mutations
were excluded, and the minimum read depth was set at
500. The polyPhen score, which represent the probability of the impact of an amino acid substitution on the
protein structure and function, was indicated for each
variant.

2.6. Sequencing and bioinformatics of cfDNA
QIASeq Targeted DNA Custom Panel (CDHS12967Z-1243) containing the same panel of 30 melanoma-associated genes with similar regions of interest
was used to determine the mutational profile of a subset of ctDNA samples. Isolated DNA was quantified
with Quant-iT dsDNA High-Sensitivity Assay Kits
(Life Technologies, Carlsbad, CA, USA) or Quant-iT
dsDNA BR Assay Kits (Life Technologies).
QIASeq Targeted DNA Panel Kits were used for
library generation and target enrichment. Fragment
size distribution of the libraries was determined with an
Agilent Bioanalyzer using a DNA 7500 chip (Agilent
Technologies, Santa Clara, CA, USA). Library quantification was performed using a KAPA Library Quantification Kit for Illumina Platforms (Roche, Basel,
Switzerland). Indexed sample libraries were equimolarly pooled and sequenced on an Illumina NextSeq
sequencer using a NextSeq 500 Mid Output v2 Kit (300
cycles). Data analysis including alignment to the reference genome and variant calling was carried out using
QIAseq Target DNA online portal and INGENUITY VARIANT ANALYSIS software (Qiagen, Hilden, Germany).
Concordance was defined as detecting an identical
single nucleotide variation (SNV) in plasma relative to
tissue in regions that were covered by both targeted
amplicon sequencing panels used for NGS of tissue
and plasma biopsies. Discordance was defined as
SNVs detected only in plasma or tumor tissue. Concordance of SNVs found in plasma that were detectable in tissue by NGS (Fig. S2) was calculated for
each tissue/plasma pair using the formula:
Concordance ð%Þ ¼ ðx  yÞ  100
x = number of variants confirmed in plasma and
tissue; y = total number of variants detected in
plasma.
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supernatant. Statistical analyses were performed using
version 5.

2.7. Droplet digital PCR

GRAPHPAD PRISM

Commercially available and/or customized probes were
used to analyze ctDNA by ddPCR. Droplets were generated using an Automatic Droplet generator QX200
AutoDG (Bio-Rad, Hercules, CA). Amplifications were
performed using cycling conditions previously described
(Gray et al., 2015; McEvoy et al., 2017). For DPH3
mutation analysis, the following probe and primer
design was used: forward primer sequence: GGG CTC
GGC ATC ATC AG, reverse primer sequence: CCG
CTA CCG GTT ATC CAT TT, DPH3 c.C8T probe:
/56-FAM/TAG CTC TTC/ZEN/CGG CGC A/
3IABkFQ/, DPH3 WT probe: /5HEX/TAG CCC
TTC/ZEN/CGG CGC A/3IABkFQ/, from Integrated
DNA Technologies (Coralville, IO, USA). Primers and
probes for TERT ctDNA analysis were as previously
reported (McEvoy et al., 2017). Levels of ctDNA per
loci were defined based on the level of false-positive
droplets in at least 12 healthy controls (Table S5).
2.8. Cell culture
UACC62 cells were obtained from NCI’s Development
Therapeutics Program; 1205Lu cells were obtained from
Meehard Herlyn, The Wistar Institute; and C037 and
A07 cells were obtained from Chris Schmidt, QIMR
Berghofer Medical Research Institute. Cells were grown
in T-25 cell culture flasks and cultured in DMEM medium fortified with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin. Cells were primarily seeded
at 5 x 105 cells per T25 flask and supplemented with
5 mL media. Cells were cultured for 72 h at 37 °C with
5% CO2. At the end of the incubation, the growth medium was collected in 15-mL nuclease-free tubes. Supernatant was isolated using a dual centrifugation
protocol, spinning at 300 9 g for 20 min followed by a
second spin at 4700 x g for 10 min. The samples were
then stored at 80 °C until extraction. Supernatant
cfDNA was extracted using QIAamp Circulating
Nucleic Acid Kits (Qiagen, Hilden, Germany) and then
were purified using Agentcour AMPure XP beads
(Beckman Coulter, Brea, CA, USA) primarily at 0.6 : 1
bead to eluted DNA volume ratio to separate large fragment size (>700 bp). Supernatant was then transferred
to another tube and further purified at 1.6 : 1 ratio to
isolate fragments within the 100–300 bp range.
2.9. Statistics
Unpaired two-tailed t-test was used to compare the
levels of TERT and DPH3 promoter ctDNA relative
to internal exonic gene region controls from cell line
174
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3. Results
3.1. Mutational profile of melanoma tumors
FFPE tumor tissue from twenty-four stage IV melanoma was first analyzed for somatic mutations using a
custom amplicon sequencing panel targeting 950
amplicons over 30 commonly mutated genes in melanoma (Table S1). Somatic mutations were identified in
20 of the samples, and four samples did not have identifiable somatic mutations within the loci analyzed
(Fig. 1). Table 1 highlights the clinical characteristics
of patients analyzed.
Six of 24 (25%) cases had mutations in BRAF p.V600
(Fig. 1). The BRAF sequence variants identified in the
tumors (N = 6) via sequencing were an exact match to
the variant annotated in the archival pathology reports.
The uveal melanoma case (MM270) included in the
study had a GNAQ p.Q209L mutation, which is commonly found in this melanoma subtype (Robertson
et al., 2018). We also observed a high frequency of
patients with deleterious mutations (polyPhen score
>0.7) in GRM3 (38%), TERT promoter (33%), NRAS
(25%), NF1 (21%), and TP53 (21%) (Fig. 1, Table S2).
In patients with TERT promoter and NRAS mutations,
the variants were found in the hotspot positions of the
promoter region (C250T/C228T) and codon 61 (p.Q61),
respectively. There were also high numbers of patients
with variants in MECOM (33%), ARID1B (25%),
and PIK3CA (21%), but the polyPhen scores indicated
benign or tolerable effects on protein function.
Five of the 24 patients analyzed harbored cosmicannotated mutations in TP53: p.R248W, p.R248Q,
p.S127F, p.S46F, and p.G266R. GRM3 and NF1 were
mutated at 38% and 21%, respectively, with mutations
distributed along the gene coding regions, consistent
with their tumor suppressor nature. Four of the mutations in these genes, GRM3 p.D548N, GRM3
p.R668H, NF1 p.W336T, and NF1 p.P1851S, have
been reported previously in COSMIC and/or TCGA
studies of melanoma (TCGA, 2015). In line with previous reports (Cirenajwis et al., 2017; TCGA, 2015),
patients bearing NF1 mutations had higher median
mutational burden compared to other patients in this
cohort (P = 0.019) (Fig. S1). The majority of mutations in these genes were not previously described, but
their polyPhen scores indicate that the changes should
have deleterious effects (Table S2).
Overall, our custom sequencing panel targeting commonly mutated genes in melanoma was effective in
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Fig. 1. Mutational profiles of 24 FFPE melanoma tumors assessed using a custom targeted sequencing panel. The percentage of patients
with alterations per gene are noted under frequency.

providing mutational information in most patients,
allowing for identification of targetable mutations for
ctDNA analyses in patients WT for BRAF and NRAS.
3.2. ctDNA detection in melanoma using multiple
mutational targets
Once the mutational profile of tumor tissues was identified, we screened the matching plasma samples of
patients for the presence of the identified mutations in
ctDNA using ddPCR. The length of time between tissue biopsy and blood collection was indicated in
Table S4. The selection of mutational targets for
ctDNA analysis was based on the following criteria:
(a) known melanoma hotspot mutation in BRAF,
NRAS, and/or TERT promoter; (b) COSMIC/TCGA
reported mutation; (c) other mutation with a polyPhen
score >0.7 and high variant allele frequency (VAF) in
the tumor.
Analysis of plasma ctDNA showed that 14 of 20
(70%) patients with mutational data had detectable

ctDNA at baseline (Table 2). In cases where two
mutational targets were analyzed (N = 13), both mutations were found either present or absent in the
ctDNA of patients, with the exception of MM362
where the TERT promoter mutation was not detectable in plasma. Interestingly, patients with readily
detectable ctDNA were found to have multiple metastases distributed at various body sites including liver,
lungs, and bones (Table 2). In contrast, patients that
were ctDNA negative at baseline were found to predominantly have lymph node metastases, with the
exception of MM372 which had a single lung metastasis and exclusion of patient MM270 (uveal melanoma).
3.3. Concordance of mutations in tissue and
plasma
Concordance of mutations in tissue and plasma was
then further analyzed in 7 of the patients who had
detectable ctDNA and sufficient plasma available
(Table 2). The mutation profile of these plasma
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Table 1. Characteristics of melanoma patients with tissue and
ctDNA mutational data.

Melanoma type
Cutaneous
Uveal
Age
30–50
51–70
71–80
Sex
Female
Male
M classification
M1a
M1b
M1c
M1d
BRAF status
BRAF Mutant
BRAF wild-type
Mutational profiling
Mutation found
No mutation found
ctDNA detection at baseline
Positive
Negative
Not tested

N

Percentage

23
1

96
4

2
12
10

8
50
42

5
19

21
79

6
6
10
2

25
25
42
8

6
18

25
75

20
4

83
17

14
6
4

58
25
17

samples was determined using a custom sequencing
panel, targeting the same loci as the panel used to analyze FFPE tumor tissues but incorporating molecular
unique identifiers to enable the detection of low frequency mutations in plasma ctDNA (Table S3).
On average, 89% (range 75–100%) of SNVs found
in the plasma of patients by targeted sequencing were
also detected in the tumor tissue (Fig. S2). Only three
mutations found in plasma were not identified in the
matching tumor (Table 3). If mutations that were in
the tissue but not in plasma are included in the concordance evaluation, that is, the number of overlapping SNVs relative to the overall number of plasma
plus tissue mutations, average concordance is reduced
to 67%, with a range of 30–100% (Table 3 and
Fig. S2). In particular, TERT promoter mutations
were not detected in plasma by NGS, but detected by
ddPCR in four of the five discordant cases (Table 2).
The TERT promoter region is difficult to amplify due
to its high GC content, and the mutant reads from this
locus were below threshold in the NGS analysis. If
positivity by ddPCR is included in the concordance
analysis between mutations found in plasma and tissues, the overall concordance between plasma and tissue biopsies is 80% (range 40–100%).
176
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The major contributor to discordance was case
MM080, with 5 SNVs found in tumor but not in plasma.
In this case, there was a 3-year gap between tissue and
blood sampling, and thus, the high number of mutations
found only in the tumor is possibly the result of clonal
evolution. Overall, these data indicate that ctDNA is
readily detectable in stage IV melanoma patients with
multiple metastatic sites. The high detection rate of
tumor-associated mutations in plasma prior to treatment
further reinforces the utility of ctDNA for genetic profiling as a potential surrogate for solid tumor biopsy.
3.4. ctDNA monitoring of melanoma patients
using single or multiple mutational targets
To investigate the utility of ctDNA as a surveillance biomarker in melanoma patients undergoing systemic therapy, patients were monitored longitudinally for ctDNA
via ddPCR targeting multiple mutations using the selection criteria described above. In the case of MM312, who
presented with isolated nodal disease in the groin, NRAS
p.Q61R mutation was undetectable in plasma ctDNA at
baseline but became detectable upon further progression
of disease (PD) (Fig. 2). Nonetheless, ctDNA was only
detectable when MTB had almost doubled at week 90,
suggesting a potential effect of MTB on ctDNA detection. No decrease in ctDNA was observed in this patient
at week 132 after commencing ipilimumab/nivolumab
therapy, but a significant decline in ctDNA was observed
at week 141. Of note, the TERT promoter mutation was
undetectable in all but one of the plasma collections.
When two or more mutations were tracked during
treatment, the ctDNA kinetics of these mutations
showed overlapping or parallel curves that were similarly
consistent with clinical response (Fig. 2), irrespective of
whether they were bona fide melanoma drivers (BRAF,
NRAS, and/or TERT) or rare deleterious mutations in
melanoma (TP53 p.R248Q, FLT1 p.T543I, KIT
p.L576P). In general, changes in ctDNA levels corresponded with the changes in MTB of patients during
treatment (Fig. 2). For example, patient MM475
(Fig. 2) had multiple recognized melanoma driver mutations including BRAF p.V600R, RAC1 p.P29S,
MAP2K1 p.P124S, TERT C228T, and DPH3 C8T. All
of these mutations decreased in concordance with
response to BRAF and MAPK inhibition and correlated
with a declining MTB. The concentration of all five
mutations greatly increased in plasma at week 23, corresponding to a small increase in MTB. At progression
(week 24), BRAF p. V600R was at 10-fold higher concentration than RAC1 and MAPK2 mutations, suggesting a
gain in copy number, which is a common mechanism of
resistance to BRAF inhibition (Johnson et al., 2015).
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Mutation

BRAF p.V600K
NRAS p.Q61K
BRAF p.V600E
BRAF p.V600R
BRAF p.V600E
BRAF p.V600K
NRAS p.Q61K
NRAS p.Q61L
KIT p.L576P
TP53 p.R248Q
BRAF p.V600E
NRAS p.Q61K
KIT p.V599A
NRAS p.Q61K
KIT p.W557R
RAC1 p.P29S
NRAS p.Q61R
CTNNB1 p.D32N
TP53 p.R248W
GNAQ p.Q209L

Patient

MM080
MM364
MM225
MM475
MM469
MM182
MM362
MM555
MM522
MM289
MM170
MM358
MM320
MM237
MM313
MM372
MM312
MM335
MM558
MM270

58
63
12
46
24
43
89
46
29
36
26
61
49
26
69
59
50
12
24
28

Tissue
Allelic
frequency
(%)
4328
2064
1695
380
233
540
390
98
56
48
33
22
13
4
0
0
0
0
0
0

Level
(cmL1)

ctDNA

38%
34%
38%
9%
8%
15%
7%
4%
4%
1%
1%
5%
1.2%
0.1%
0
0
0
0
0
0

Allelic
frequency
(%)
66

48
54
48
24
23
36
80
23
36
44
37
22

TERT C250T

RAC1 p.P29S
GRM3 p.P605S
TERT C250T
TERT C250T
TERT C228T
FLT1 p.T543I
TP53 p.S127F
DDX3X p.R475C
PIK3CA p.S326F
TERT C228T
TERT C250T
NF1 p.P1851S

Mutation

Tissue
Allelic
frequency
(%)
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0
0

20
2
9
0

720
0
16
11
18

446

1080

Level
(cmL1)

ctDNA

0
0

3
0.1
1
0

12
0
2
4
1

12

20

Allelic
frequency
(%)

Table 2. Levels of ctDNA at baseline and the distribution of melanoma metastasis across body sites.

x

Brain

x

x
x

x
x

x
x

x

Bone

x
x

x
x

x

Liver

Sites of metastasis

x

x

x

x

x
x
x

x
x
x

Lung

x
x
x

x

x
x

x
x
x

x

x

Lymph
Node

x

x

x
x

x
x

Mesentery

x

Pancreas

x

x
x

Pelvic
Region

x

x

x
x

x

x

Subcutaneous
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177

178
30
40

20

a

11
3

9

66

49

15

5
15

1

25

4
58

4

1
100
100

5

4

80

61

61

Tissue

67
67

7

3

ctDNA

MM362

48

89

85

Tissue

75
75

3

3
6

8

ctDNA

MM469

4
40

30

Tissue

83
100

2a

8

4

1

8

2

ctDNA

MM475

60

48

19

14

46

17

Tissue

a

Boxes denote frequency abundance (%) of each SNV detected by NGS in tissue only (blue), plasma only (light red), or in both biopsies (dark red).
Denotes SNV in ctDNA detected by ddPCR but not NGS.

ARID1B p.P1491L
ARID1B p.P1006L
ARID1B p.I1666T
ARID2 p.T969I
BRAF p.V600K
BRAF p.V600E
BRAF p.V600R
DDX3X p.I195N
FLT1 p.G706E
FLT1 p.T335P
GRM3 p.D548N
GRM3 p.D744N
KIT p.L576P
KMT2A p.R1630Q
KMT2A p.D2893E
MAP2K1 p.P124S
MECOM p.S419F
MECOM p.R748Q
MECOM p.P701S
NF1 p.I1624L
NF1 p.P1421L
NF1 p.L792F
NRAS p.Q61K
NRAS p.Q61L
RAC1 p.P29S
SETD2 p.S917N
TERT C228T
TERT C250T
TP53 p.S127F
Concordance (NGS only)
Concordance (NGS + ddPCR)

ctDNA

ctDNA

Tissue

MM358

MM080

Table 3. Single nucleotide variation profile derived from NGS of 7 melanoma patients with matched FFPE tissue and plasma.
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Fig. 2. Monitoring ctDNA levels in melanoma patients undergoing systemic therapy. Plasma ctDNA levels were determined using two
mutations and compared to FDG-PET metabolic tumor burden (MTB). Therapies are indicated by colored boxes. Disease status by
radiological imaging is indicated by arrows and labeled as PR: partial response, PD: progressive disease, or CR: complete response. For
patient MM475, PET scan images corresponding to clinical responses are shown above.

Molecular Oncology 13 (2019) 171–184 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

179

Concordance of melanoma mutational landscape in tissue and ctDNA

These results indicate that well-known driver mutations or infrequent deleterious mutations can be used
for ctDNA-based patient surveillance, given their close
correlation with changes in MTB.
3.5. TERT ctDNA is represented in lower levels in
plasma
Longitudinal monitoring of patients with detectable
TERT ctDNA (Fig. 2) revealed lower copies of these
mutations in plasma compared to that of other driver
mutations. In fact, of the 6 patients confirmed to harbor
TERT promoter mutations as well as another driver

L. Calapre et al.

mutation in their tumor tissue, TERT-mutated ctDNA
was underrepresented or undetectable in plasma relative
to the levels of the other mutation analyzed (Fig. 3A).
Given the location of these mutations within a promoter
region, we hypothesized that the underrepresentation of
TERT copies in plasma ctDNA is a result of low nucleosome occupancy at these sites, providing a lack of protection of this region against nuclease cleavage during
cell apoptosis (Ulz et al., 2016).
We therefore conducted in vitro experiments using
the melanoma cell lines 1205Lu and UACC62, which
are known to carry TERT promoter C228T and C250T
mutations, respectively, to determine whether similar

Fig. 3. Differential levels of promoter mutations in ctDNA. (A) Comparison of the TERT promoter mutations allelic frequency (AF) in tumor
tissue and copies per mL of plasma relative to the major driver mutation in six melanoma patients. (B–E) Bar graphs of the absolute copy
number of intragenic or promoter region of TERT in 1205Lu and UACC62 gDNA and supernatant ctDNA (B, C) or intragenic or promoter
region of DPH3 in C032 and A07 gDNA or supernatant ctDNA (D, E). Standard deviations of triplicate experiments are indicated. P values
≥0.05 (unpaired t-test) were considered as statistically significant.
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patterns of underrepresentation of the TERT promoter
regions are observed in the DNA isolated from the
supernatant of these cell lines. We found no difference
in the ratio of absolute copies of the intragenic TERT
and the promoter region in the genomic DNA of these
cells (Fig. 3B). However, there were significant differences in the copies of promoter TERT vs intragenic
TERT in supernatant-derived ctDNA for both cell lines
(P = 0.012), with more than fivefold less TERT promoter copies compared intragenic TERT (Fig. 3C).
Recently, mutations in the DPH3 promoter region
have been found in 10% of melanomas (Denisova
et al., 2015). Given its location, we determined
whether the DPH3 promoter region is also underrepresented in plasma. We screened our patient cohort for
DPH3 mutations, and similarly, we found underrepresentation of this promoter mutation in the blood of
patient MM475 (Fig. 2). To further validate these findings in vitro, we then tested the supernatant from A07
and C032 melanoma cell lines that were found to carry
the DPH3 C8T promoter mutation. We again found a
significantly lower number of absolute copies of DPH3
promoter compared to exonic DPH3 in the supernatant cfDNA of A07 (P = 0.048) and C032
(P = 0.022) cell lines (Fig. 3D). The overall copies of
exonic and promoter regions of DPH3 were found at
approximately similar levels in genomic DNA from
the cells (Fig. 3E). Notably, these experiments highlight the variability in representation of different loci
in cfDNA, which can impact the detection of promoter
region mutations in plasma ctDNA.

4. Discussion
Multiple studies over the last three years have provided
increasing evidence of the value of ctDNA for monitoring treatment response in metastatic melanoma patients
(Ascierto et al., 2013; Girotti et al., 2016; Gray et al.,
2015; Knol et al., 2016; Schreuer et al., 2016) but mostly
relied on a few common driver mutations to determine
disease status for ctDNA analysis. Therefore, improved
methods that allow interrogation of multiple genes
together with further studies are required to determine
the concordance of genetic aberrations in matched tissue
and plasma biopsies in melanoma patients.
In this study, we validated a targeted sequencing
panel, comprised of 30 melanoma-associated genes, and
compared the mutation profiles in tumor tissue and
plasma across multiple patients prior to therapy commencement. We demonstrated a high level of concordance between tissue and plasma biopsies, supporting
the use of ctDNA as a suitable surrogate for genetic
profiling. We reported on the kinetics of ctDNA using

multiple targeted mutations within the same patient
throughout treatment response and disease progression.
Importantly, we provided clinical and in vitro evidence
of the underrepresentation in ctDNA of mutations in
promoter regions such as those of TERT and DPH3.
All these findings need to be considered for the clinical
implementation of ctDNA as a monitoring tool for melanoma. Our results are of particular significance for
patients who are negative for BRAF mutations, as we
show that other mutations can be used for tumor monitoring.
Given the high mutational heterogeneity of melanoma tumors, the use of comprehensive and targeted
NGS technologies for molecular profiling proved
highly beneficial. With these, we characterized the
landscape of mutations in the tissue and peripheral
blood to identify molecular targets for patient surveillance. Our panel was able to identify clinically relevant
somatic variants in 83% of patients, suggesting high
efficiency for identifying targetable mutations for longitudinal ctDNA monitoring.
We found a high proportion of metastatic melanoma patients had detectable ctDNA at baseline and
that genomic alterations in peripheral blood in
ctDNA-positive patients were highly concordant with
those in the tissue. We acknowledge that our conclusions are based on a small sample size, including only
seven tissue and plasma ctDNA pairs for NGS analysis. However, our results add to the mounting evidence
on the potential utility of ctDNA as a surrogate to
solid tumor biopsy and as an ideal candidate for
molecular analysis as previously demonstrated for various cancers (Chae et al., 2017; Goldberg et al., 2018;
Jovelet et al., 2016; Murtaza et al., 2015; Wong et al.,
2017). Notably, we observed a bias towards ctDNA
detectability in patients with high metastatic burden.
Patients with an isolated metastasis, particularly in the
lymph nodes, consistently had no detectable ctDNA at
baseline, which constitutes a limitation to the use of
plasma ctDNA in the clinic (De Mattos-Arruda et al.,
2015; Li et al., 2016; Momtaz et al., 2016).
It is also important to note that we found few SNVs
in plasma only, which is in line with the idea that
ctDNA is representative of the sum of the multiple
tumor lesions and clones. While we did not assess the
mutational profile of multiple metastases, this result is
consistent with studies in melanoma and other cancers
detailing the capacity of ctDNA to comprehensively
capture tumor heterogeneity (Bettegowda et al., 2014;
FitzGerald et al., 2017; Murtaza et al., 2015; Wong
et al., 2017). Our results also highlighted high discordance in the mutational profile of a patient with a large
gap between tissue and blood collection, suggesting
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potential impact of clonal evolution on the concordance
of tissue and plasma biopsies. Thus, changes in the
somatic mutational landscape, as part of disease evolution, must be taken in consideration when monitoring
cases where new metastases are inaccessible and selection of targetable mutations for monitoring melanoma
patients or treatment selection depends on the primary
tumor.
Notably, the kinetics of multiple ctDNA targets,
particularly melanoma driver mutations, uniformly
informed on tumor dynamics in response to treatment.
These results underscore the fact that well-known and/
or rare driver mutations can be used for ctDNA quantification and patient surveillance. These findings are
in contrast to a previous study by Gremmel et al.
describing a case of mucosal melanoma with two distinct tumor subclones, identified by whole exome
sequencing, with differential response to imatinib,
chemotherapy, and immunotherapy (Gremel et al.,
2016). However, the use of a limited number of targeted loci in our study may have constrained our ability to fully capture tumor heterogeneity. Another
limitation of our study is that only a single metastasis
was analyzed from each patient to obtain the mutational data used for ctDNA surveillance. While the
ctDNA kinetics of driver mutations may be used to
determine systemic response to treatment, there is a
possibility that subclones prevalent in other metastases
may serve as a good indicator of the specific response
of individual metastatic deposits to therapy.
Significantly, our data call for caution when interpreting ctDNA levels based on single locus analysis, particularly in the context of promoter mutation targets.
Previous research has observed the presence of lower
copies of TERT ctDNA relative to other mutations
(McEvoy et al., 2017; Wong et al., 2017). Herein, we
also found a similar pattern of TERT and DPH3 promoter underrepresentation in cell-free DNA in vivo and
in vitro. Ulz et al. (2016) previously reported that promoters of transcriptionally active genes are often devoid
of nucleosomes and can induce variability in plasma
cfDNA. Thus, the biological process of cfDNA biogenesis may significantly affect quantitative-based applications for liquid biopsy, particularly for patient
monitoring. Nevertheless, as mutations in the TERT
promoter enhance TERT expression, which is associated
with poor disease-free and melanoma-specific survival
(Nagore et al., 2016), low levels of TERT promoter
mutation in cfDNA relative to other activating
mutations may be harnessed to delineate patients with
transcriptionally active TERT. Overall, our results
underscore the need for further studies into ctDNA biology prior to its clinical implementation.
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5. Conclusions
Overall, ctDNA has significant clinical value as a noninvasive source of genetic material for mutational analyses, which can guide treatment selection, and for
identification of traceable markers for patient monitoring in melanoma. Its ease of access and relative ability
to accurately reflect disease burden make it a particularly reliable biomarker for the surveillance of melanoma patients during treatment course.

Acknowledgements
We would like to thank the melanoma patients for
their participation and support of the study. We
extend our thanks to Aaron Beasley, Jamie Freeman,
Danielle Bartlett, and Pauline Zaenker for their help
in the collection and processing of patient blood samples. This study was funded by an NHMRC Grant
(1117911) obtained by MZ, NH, MM, BA, EG, MK,
and a Cancer Council Grant (1100249) awarded to
EG, MZ, MM as well as grants to MZ, EG, MM,
MK, BA from the Department of Health Western
Australia, the Spinnaker Foundation and the Perpetual
Foundation. This study was also funded by ECU
Early Career Research grant awarded to LC. EG is
supported by a fellowship from the Cancer Research
Trust. NKH is supported by an NHMRC Senior Principal Research Fellowship.

Conflict of interest
The authors declare no conflict of interest.

Author contribution
LC, EG, and MZ conceived and designed the project.
LC, EG, GT, CR, and BA conducted the experiments
and analysis of the results. AR and MR were involved
in sample preparation and analysis of results. NH provided the DPH3-mutant cell lines and contributed to
the study design. MM, MAK, and TMM recruited the
patients. MM, MAK, TMM, LW, ZA, and AM
helped in clinical data analysis and provided feedback
on patient clinical status. All authors provided feedback, revised, and approved the final manuscript.

References
Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A,
Arya N, Guckert M, Schadendorf D, Kefford RF,
Grob JJ et al. (2013) Phase II trial (BREAK-2) of the

Molecular Oncology 13 (2019) 171–184 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

L. Calapre et al.

Concordance of melanoma mutational landscape in tissue and ctDNA

BRAF inhibitor dabrafenib (GSK2118436) in patients
with metastatic melanoma. J Clin Oncol 31, 3205–3211.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y,
Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM
et al. (2014). Detection of circulating tumor DNA in
early- and late-stage human malignancies. Sci Translat
Med 6, 224ra224.
Calapre L, Warburton L, Millward M, Ziman M and Gray
ES (2017) Circulating tumour DNA (ctDNA) as a
liquid biopsy for melanoma. Cancer Lett 404, 62–69.
Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L,
Beaubier N, Platanias LC, Gradishar W, Giles FJ and
Cristofanilli M (2017) Concordance of genomic
alterations by next-generation sequencing in tumor
tissue versus circulating tumor DNA in breast cancer.
Mol Cancer Therap 16, 1412–1420.
Chen HH, Chiu NT, Su WC, Guo HR and Lee BF (2012)
Prognostic value of whole-body total lesion glycolysis
at pretreatment FDG PET/CT in non-small cell lung
cancer. Radiology 264, 559–566.
Chen G, McQuade JL, Panka DJ, Hudgens CW, AminMansour A, Mu XJ, Bahl S, Jane-Valbuena J, Wani
KM, Reuben A et al. (2016) Clinical, molecular, and
immune analysis of Dabrafenib-Trametinib
combination treatment for BRAF inhibitor-refractory
metastatic melanoma: a phase 2 clinical trial. JAMA
Oncol 2, 1056–1064.
Cirenajwis H, Lauss M, Ekedahl H, Torngren T, Kvist A,
Saal LH, Olsson H, Staaf J, Carneiro A, Ingvar C
et al. (2017) NF1-mutated melanoma tumors harbor
distinct clinical and biological characteristics. Mol
Oncol 11, 438–451.
De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, MartinezRicarte F, Torrejon D, Oliveira M, Arias A, Raventos C,
Tang J et al. (2015) Cerebrospinal fluid-derived circulating
tumour DNA better represents the genomic alterations of
brain tumours than plasma. Nat Communicat 6, 8839.
Denisova E, Heidenreich B, Nagore E, Rachakonda PS,
Hosen I, Akrap I, Traves V, Garcia-Casado Z, LopezGuerrero JA, Requena C et al. (2015) Frequent DPH3
promoter mutations in skin cancers. Oncotarget 6,
35922–35930.
FitzGerald LM, Naeem H, Makalic E, Schmidt DF, Dowty
JG, Joo JE, Jung CH, Bassett JK, Dugue PA, Chung J
et al. (2017) Genome-wide measures of peripheral blood
Dna methylation and prostate cancer risk in a prospective
nested case-control study. Prostate 77, 471–478.
Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D,
Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ
et al. (2016) Application of sequencing, liquid biopsies,
and patient-derived Xenografts for personalized
medicine in melanoma. Cancer Discov 6, 286–299.
Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J,
Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM
et al. (2018) Early assessment of lung cancer

immunotherapy response via circulating tumor DNA.
Clin Cancer Res 24, 1872–1880.
Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J,
Tembe V, Freeman J, Lee JH, Scolyer RA et al. (2015)
Circulating tumor DNA to monitor treatment response
and detect acquired resistance in patients with
metastatic melanoma. Oncotarget 6, 42008–42018.
Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S,
Garner G, Ayub M, Wood S, Rothwell DG, Fusi A
et al. (2016) Distinct subclonal tumour responses to
therapy revealed by circulating cell-free DNA. Annals
Oncol 27, 1959–1965.
Haselmann V, Gebhardt C, Brechtel I, Duda A,
Czerwinski C, Sucker A, Holland-Letz T, Utikal J,
Schadendorf D and Neumaier M (2018) Liquid
profiling of circulating tumor DNA in plasma of
melanoma patients for companion diagnostics and
monitoring of BRAF inhibitor therapy. Clin Chem 64,
830–842.
Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F,
Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R
et al. (2015) Acquired BRAF inhibitor resistance: a
multicenter meta-analysis of the spectrum and
frequencies, clinical behaviour, and phenotypic
associations of resistance mechanisms. Europ J Cancer
51, 2792–2799.
Jovelet C, Ileana E, Le Deley MC, Motte N, Rosellini S,
Romero A, Lefebvre C, Pedrero M, Pata-Merci N,
Droin N et al. (2016) Circulating cell-free tumor DNA
analysis of 50 genes by next-generation sequencing in
the prospective MOSCATO trial. Clin Cancer Res 22,
2960–2968.
Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH,
Kim DW, Lee DS, Kim CW, Chung JK et al. (2013)
Total lesion glycolysis in positron emission
tomography is a better predictor of outcome than the
International Prognostic Index for patients with diffuse
large B cell lymphoma. Cancer 119, 1195–1202.
Knol AC, Vallee A, Herbreteau G, Nguyen JM, Varey E,
Gaultier A, Theoleyre S, Saint-Jean M, Peuvrel L,
Brocard A et al. (2016) Clinical significance of BRAF
mutation status in circulating tumor DNA of
metastatic melanoma patients at baseline. Exp
Dermatol 25, 783–788.
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I,
Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC,
Gogas H et al. (2014) Vemurafenib in patients with
BRAFV600 mutated metastatic melanoma: an openlabel, multicentre, safety study. Lancet Oncol 15, 436–
444.
Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V,
Guminski A, Jakrot V, Scolyer RA, Mann GJ et al.
(2017) Circulating tumour DNA predicts response to
anti-PD1 antibodies in metastatic melanoma. Ann
Oncol 28, 1130–1136.

Molecular Oncology 13 (2019) 171–184 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

183

Concordance of melanoma mutational landscape in tissue and ctDNA

Li Y, Pan W, Connolly ID, Reddy S, Nagpal S, Quake S
and Gephart MH (2016) Tumor DNA in cerebral
spinal fluid reflects clinical course in a patient with
melanoma leptomeningeal brain metastases. J NeuroOncol 128, 93–100.
Luke JJ, Flaherty KT, Ribas A and Long GV (2017)
Targeted agents and immunotherapies: optimizing
outcomes in melanoma. Nat Rev Clin Oncol 14, 463–
482.
McEvoy A, Calapre L, Pereira MR, Giardina T, Robinson
C, Khattak M, Meniawy T, Pritchard AL, Hayward
NK, Amanuel B et al. (2017) Sensitive droplet digital
PCR method for detection of TERT promoter
mutations in cell free DNA from patients with
metastatic melanoma. Oncotarget 8, 78890–78900.
Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E,
Hyman D, Merghoub T, You D, Gasmi B, Viale A and
Chapman PB (2016) Quantification of tumor-derived
cell free DNA(cfDNA) by digital PCR (DigPCR) in
cerebrospinal fluid of patients with BRAFV600 mutated
malignancies. Oncotarget 7, 85430–85436.
Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM,
Provenzano E, Grant J, Chin SF, Tsui DW, Marass F,
Gale D et al. (2015) Multifocal clonal evolution
characterized using circulating tumour DNA in a case
of metastatic breast cancer. Nat Communicat 6, 8760.
Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado
Z, Requena C, Soriano V, Frank C, Traves V,
Quecedo E and Sanjuan-Gimenez J (2016) TERT
promoter mutations in melanoma survival. Int J
Cancer 139, 75–84.
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M,
Robbins CM, Moses TY, Hostetter G, Wagner U,
Kakareka J et al. (2002) High frequency of BRAF
mutations in nevi. Nat Genet 33, 19.
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid
O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis
KD et al. (2015) Pembrolizumab versus investigatorchoice chemotherapy for ipilimumab-refractory
melanoma (KEYNOTE-002): a randomised, controlled,
phase 2 trial. Lancet Oncol 16, 908–918.
Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall
KL, Hess JM, Uzunangelov V, Walter V, Danilova L
et al. (2018) Integrative analysis identifies four
molecular and clinical subsets in uveal melanoma.
Cancer Cell 32, 204–220.e215.
Sanmamed MF, Fernandez-Landazuri S, Rodriguez C,
Zarate R, Lozano MD, Zubiri L, Perez-Gracia JL,
Martin-Algarra S and Gonzalez A (2015) Quantitative
cell-free circulating BRAFV600E mutation analysis by
use of droplet digital PCR in the follow-up of patients

184

L. Calapre et al.

with melanoma being treated with BRAF inhibitors.
Clin Chem 61, 297–304.
Santiago-Walker A, Gagnon R, Mazumdar J, Casey M,
Long GV, Schadendorf D, Flaherty K, Kefford R,
Hauschild A, Hwu P et al. (2016) Correlation of BRAF
mutation status in circulating-free DNA and tumor and
association with clinical outcome across four BRAFi
and MEKi clinical trials. Clin Cancer Res 22, 567–574.
Schreuer M, Meersseman G, Van Den Herrewegen S,
Jansen Y, Chevolet I, Bott A, Wilgenhof S, Seremet T,
Jacobs B, Buyl R et al. (2016) Quantitative assessment
of BRAF V600 mutant circulating cell-free tumor
DNA as a tool for therapeutic monitoring in
metastatic melanoma patients treated with BRAF/
MEK inhibitors. J Translat Med 14, 95.
TCGA (2015) The cancer genome atlas network, genomic
classification of cutaneous melanoma. Cell 161, 1681–
1696.
Tsao H, Chin L, Garraway LA and Fisher DE (2012)
Melanoma: from mutations to medicine. Genes Develop
26, 1131–1155.
Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K,
Jahn SW, Abete L, Pristauz G, Petru E, Geigl JB
et al. (2016) Inferring expressed genes by wholegenome sequencing of plasma DNA. Nat Genet 48,
1273–1278.
Wong SQ, Raleigh JM, Callahan J, Vergara IA, Ftouni S,
Hatzimihalis A, Colebatch AJ, Li J, Semple T, Doig K
et al. (2017). Circulating tumor DNA analysis and
functional imaging provide complementary approaches
for comprehensive disease monitoring in metastatic
melanoma. JCO Precis Oncol 1, 1–14.

Supporting information
Additional supporting information may be found
online in the Supporting Information section at the end
of the article.
Fig. S1. Comparison of number SNVs in patients with
and without NF1 mutations.
Fig. S2. Percent concordance of SNVs in tissue and
plasma biopsies by NGS or NGS plus ddPCR.
Table S1. Melanoma panel.
Table S2. NGS mutational profile of study cohort.
Table S3. Comparison of SNVs in tissue and plasma
biopsies.
Table S4. Time-lapse of tissue and plasma biopsies
(weeks) obtained for the study cohort.
Table S5. Specificity of ddPCR assays.

Molecular Oncology 13 (2019) 171–184 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

